| AUR103 Calcium in Advanced Neuroendocrine Tumours (BHARAT-3 Study) (NCT07640737) | Aurigene Discovery Technologies Limited | 2026-06-30 |
| A Phase 1b/2 Clinical Trial Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AUR103 Calcium in Patients With HER2-positive Advanced Gastric/Gastroesophageal Junction Adenocarcinoma (NCT07040059) | Aurigene Discovery Technologies Limited | 2025-03-22 |
| Study Evaluating Safety Pharmacokinetics and Pharmacodynamics of AUR112 in Patients With Relapsed Advanced Lymphoma (NCT06755450) | Aurigene Discovery Technologies Limited | 2025-01-15 |
| A Study of AUR104 in Patients With Relapsed/Refractory Lymphoid Malignancies (VIJAY-1) (NCT06761586) | Aurigene Discovery Technologies Limited | 2024-12-12 |
| A Study Evaluating the Safety and Efficacy of AUR108 in Patients With Relapsed Advanced Lymphomas (ASHA-1) (NCT05984147) | Aurigene Discovery Technologies Limited | 2023-10-19 |
| A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1) (NCT05865002) | Aurigene Discovery Technologies Limited | 2023-09-05 |
| A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies (NCT05861947) | Aurigene Discovery Technologies Limited | 2023-08-26 |
| First in Human, Dose Escalation, Dose Expansion Study of AUR105 (NCT05605119) | Aurigene Discovery Technologies Limited | 2022-11-30 |
| A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics (NCT05607199) | Aurigene Discovery Technologies Limited | 2022-09-16 |
| A Dose-Ranging Phase II Study of AUR101 in Psoriasis (INDUS-3) (NCT04855721) | Aurigene Discovery Technologies Limited | 2021-05-04 |
| A Phase II Study to Evaluate Efficacy & Safety of AUR101 in Patients of Moderate-to-Severe Psoriasis (NCT04207801) | Aurigene Discovery Technologies Limited | 2020-01-21 |